Drug Profile
Research programme: anti-CD20 monoclonal antibody - Byondis
Alternative Names: BLX-301Latest Information Update: 21 Apr 2020
Price :
$50
*
At a glance
- Originator Biolex
- Developer Byondis
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported B-cell lymphoma
Most Recent Events
- 16 Apr 2020 Synthon Biopharmaceuticals is now called Byondis
- 04 Nov 2017 No recent reports of development identified for preclinical development in B-cell lymphoma in USA (Parenteral)
- 15 Jun 2017 MRC Technology is now called LifeArc